FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Source · https://www.globenewswire.com/news-release/2026/05/30/3303857/0/en/FSK-INVESTOR-DEADLINE-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-FS-KKR-Capital-Corp-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html

Read source

FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Search tags

What matters in this story

FS KKR Capital Corp. is facing a class action lawsuit alleging securities fraud related to misleading statements about portfolio valuations and restructuring effectiveness. — Securities litigation creates legal liability and signal potential mismanagement or accounting irregularities, typically depressing share prices.

-0.60

FS KKR reduced its quarterly dividend from $0.70 to $0.48 per share following a decline in net asset value. — Dividend cuts are strongly negative for BDCs as investors typically hold these assets for the high yield.

-0.50

The company's non-accrual investments increased to 3.4% of the total portfolio at fair value by early 2026. — Rising non-accrual rates indicate deteriorating credit quality within the portfolio and a higher risk of permanent loss.

-0.40

FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

What matters in this story

FSK UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds FS KKR Capital (FSK) Investors of Securities Class Action Deadline on July 3, 2026

FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

What matters in this story

FSK UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds FS KKR Capital (FSK) Investors of Securities Class Action Deadline on July 3, 2026

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

POET Investors Have Opportunity to Lead POET Technologies Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

CALX Investors Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit

AVAV Investors Have Opportunity to Lead AeroVironment, Inc. Securities Fraud Lawsuit

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

What matters in this story

Next reads from the same story arc

FSK UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds FS KKR Capital (FSK) Investors of Securities Class Action Deadline on July 3, 2026

FSK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

What matters in this story

Next reads from the same story arc

FSK UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds FS KKR Capital (FSK) Investors of Securities Class Action Deadline on July 3, 2026

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

POET Investors Have Opportunity to Lead POET Technologies Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

CALX Investors Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit

AVAV Investors Have Opportunity to Lead AeroVironment, Inc. Securities Fraud Lawsuit

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS